Excelestar Ventures

At Excelestar Ventures, they strive to add value to businesses seeking to expand their presence in their industry. From a portfolio perspective, they help portfolio companies realize operational efficiencies to produce growth and sustainable profits. Their team performs extensive market research and conducts consultations with industry experts in its investment due diligence process, through which they are able to secure positions in undervalued companies with proven intrinsic value. Their management approach is hands-on, continuously working with their clients to add real value. As such, Excelestar is selective in its investments in order to yield solid returns for our investors. Since its founding, Excelestar has become a global company invested in mature businesses needing capital to expand operations. They invest globally, understanding that opportunities for success are not limited by borders but made possible through efficient but robust business models. Their success lies in refining and reinvigorating those sound models.

Ibrahim Al-Qamari

Principal

Tasneem Dohadwala

Founding Partner

Emily Giudice

Principal

19 past transactions

Sealonix

Series A in 2023
Sealonix focuses on the development and commercialization of hemostatic sealants using its proprietary biomaterials. Sealonix is working on a sealant patch that will provide quick hemostasis for abdominopelvic and orthopedic operations. The PramStat patch is intended to bioabsorb within one week of implantation.

Adona Medical

Series B in 2022
Adona Medical is a privately held portfolio company of Shifamed that innovates interventional approaches for heart failure, a complex and progressive condition impacting approximately 6.5 million patients in the US and as many as 26 million patients globally. Adona's platform will overcome the shortcomings of existing treatment options and enable providers to improve care for heart failure patients.

Concerto Biosciences

Venture Round in 2022
Concerto Biosciences rebuilds microbial communities in, on, and around us to heal our bodies and our planet. Products that rebuild microbial communities do not yet exist because no one can map the vast inter-species interaction networks responsible for community behavior. Concerto’s cofounders therefore invented the first-ever ultra-high-throughput platform to experimentally measure millions of microbial interactions. Concerto maps interaction networks that reveal a new class of products called “ensembles”—combinations of microbes that work in concert to shepherd damaged microbial communities to health. The opportunities are enormous: Concerto will become the premier inventor of ensembles across medicine and agriculture, reinventing humanity’s relationship with microbes.

Chromatic 3D Materials

Venture Round in 2021
Chromatic 3D Materials is inventing the next generation of 3D printing materials with the durability to meet the requirements for finished manufactured goods. Today, their reality includes infinite possibilities for novel product designs, made possible by their customizable property range.

RoadSync

Series B in 2021
From our beginnings in 2015, RoadSync has been on an upward trajectory, quickly becoming the chosen financial solution for some of the largest names in the logistics space. Our team is standing by, ready to help you with smart, simple, and innovative financial solutions that help you modernize your commerce. RoadSync is on a mission to automate the financial solutions fueling the $800B logistics industry.

Instylla

Series B in 2020
Instylla is a medical equipment supplier that provides liquid embolics of the next generation for interventional radiology. It is a Bedford, Massachusetts-based company. independently held firm with the major objective of developing next-generation liquid embolics for the radiology department. with early medical applications in peripheral hemostasis and interventional oncology. The EmbraceTM Hydrogel Embolic System, the company's initial product, and persistent embolization in these clinical situations.

Terecircuits

Venture Round in 2020
Terecircuits develops processes and materials to support microassembly and mass transfer for displays and advanced electronics.

Adona Medical

Series A in 2020
Adona Medical is a privately held portfolio company of Shifamed that innovates interventional approaches for heart failure, a complex and progressive condition impacting approximately 6.5 million patients in the US and as many as 26 million patients globally. Adona's platform will overcome the shortcomings of existing treatment options and enable providers to improve care for heart failure patients.

Kinnos

Venture Round in 2020
Kinnos is a biotechnology company pioneering color technology to revolutionize how they use disinfectants. The company's first product, Highlight, is a point-of-use additive that greatly improves visibility and end-user compliance of disinfectants. Their goal is to empower people to disinfect surfaces with confidence and to provide society with peace of mind through disinfection they can see.

Kinnos

Series A in 2020
Kinnos is a biotechnology company pioneering color technology to revolutionize how they use disinfectants. The company's first product, Highlight, is a point-of-use additive that greatly improves visibility and end-user compliance of disinfectants. Their goal is to empower people to disinfect surfaces with confidence and to provide society with peace of mind through disinfection they can see.

Conformal Medical

Series B in 2018
Conformal Medical is an early stage medical device company developing devices to prevent stroke in patients with non-valvular atrial fibrillation. The company's proprietary technology will help left atrial appendage closure to meet its true potential. It was founded in 2016 and is headquartered in Nashua, New Hampshire.

Lantos Technologies

Venture Round in 2018
Lantos Technologies is the only FDA-cleared 3D ear scanning system that enables custom, in-ear products with superior comfort, sound quality, and performance. Our technology enables the efficient and effective delivery of customized hearing aids and other hearing-related products.

Diesel Labs

Seed Round in 2018
Diesel Labs is a content intelligence company that measures audience attention across the entire entertainment landscape to help media companies address the most tough issues they face today: what to create, where to sell, and how to measure success. Designers analyze the engagement of millions of audience members with content across all major social and video platforms, including (but not limited to) Twitter, YouTube, TikTok, Facebook, and Instagram. With us, data solutions provide a comprehensive layer of insight on which media companies rely when developing potential for enabling content and specific product categories in order to increase audience engagement and subscribership.

Altiostar Networks

Venture Round in 2017
Altiostar Networks designs equipment focused on deploying and expanding mobile network operator’s LTE networks. Altiostar Networks is a seasoned team of technology entrepreneurs with a very successful track record. The company is building an exciting array of solutions for the mobile broadband industry. Its vision and mission is to enhance communications experience and reduce the cost of technology. Altiostar Networks's highly experienced team is working on some innovative ideas.

Anova Data

Series B in 2015
Anova Data is an end-to-end 360-degree analytics framework to radically shift an operator’s position from reactive to proactive. The framework delivers out-of-the-box analytics applications allowing the operator to realize the untapped potential of network assets across a number of functions such as marketing, monetization, customer care, network assurance, and end-to-end service orchestration. Anova’s web-scale, end-to-end analytics solutions unleash the full value of subscriber and network data insight, enabling operators to get ahead of unprecedented subscriber data growth and take back control of their networks. Anova Data was founded in 2015 and is headquartered in Westford, Massachusetts.

SpaceOAR

Series D in 2014
SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.

Zettics

Series D in 2013
Zettics delivers a 360° understanding of data usage, enabling operators to extract greater value from their subscriber relationships and networks while allowing the operator to fully comply with subscriber privacy policies. Zettics enables operators to monetize data with third parties, understand trends in data usage, enrich their CRM systems, identify network abuse, analyze pricing plans, enhance advertising offers, reduce churn, forecast network usage growth, and more. Zettics products deliver over 60 use cases that provide a significant return on investment to operators.

nVision Medical

Series A in 2013
NVISION MEDICAL Corporation operates in the healthcare sector. The company was incorporated in 2009 and is based in Saratoga, California. nVision is a privately-held medical device company dedicated to filling the void in women’s health innovation. Since its founding in 2011, the company has relentlessly focused on developing devices to enable clinicians to assess the health of previously inaccessible parts of the female reproductive tract.

Sera Prognostics

Series A in 2011
Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.